InTest Q2 2026 slides: revenue beats, semi orders surge 56%

InTest posted Q2 2026 revenue of $35.3M (+9% vs $32.0M consensus) and raised full-year 2026 revenue guidance to $135M–$140M (~21% y/y growth at the midpoint vs $113.8M in 2025). The quarter showed a sharp semiconductor orders recovery, up 56% sequentially to the strongest intake in six quarters, while gross margin fell 280 bps sequentially to 40.5% due to unfavorable Auto/EV mix. Profitability improved despite margin pressure (GAAP net income $0.5M vs a $0.5M loss a year ago; adjusted EPS $0.09 vs $0.10 expected) and liquidity strengthened (cash up to $22.1M; free cash flow $5.9M vs -$1.2M). Management guided Q3 revenue of $33M–$35M with gross margin ~44%, signaling improving mix ahead.

Analysis

This is a classic high-revenue, low-quality-mix print: the market is likely reacting to the fact that incremental sales are not yet translating cleanly into earnings power. At this size, a 200-300 bp swing in gross margin matters more than a few million of extra revenue because fixed opex makes the quarter highly levered; that means the stock can re-rate quickly if Q3 margins really move back toward the mid-40s.

The cleaner beneficiaries are the semicap names and test peers with better margin structures, not necessarily INTT itself. TER, FORM, and COHU should read the order recovery as a healthier industry signal, while auto/EV-adjacent vendors may see less immediate upside as spending normalizes. The near-term technical overhang is the credit-facility deadline and the control weakness at Alfamation; neither is a solvency issue today, but both can suppress the multiple until they are visibly cleared.

The contrarian miss is that the backlog decline may be more mix cleanup than demand deterioration. Over 1-3 months, the key falsifier is a Q3 gross margin guide or print below ~42% or a renewed slowdown in semiconductor orders; over 6-18 months, sustained semi/defense mix plus footprint rationalization could turn this into a real EBITDA margin story. If that execution does not show up, this remains a trading name rather than a durable compounder.

Key Decisions for Investors

• Tactical long INTT only on weakness/retest of the post-earnings selloff; size small and use a hard stop if Q3 gross margin guidance slips below ~42% or if the credit-facility renewal is delayed beyond late August.
• Prefer TER or FORM over INTT for semiconductor-cycle exposure; if expressing the view as a pair, long TER/short INTT to own cleaner margin capture while hedging broad semi-beta.
• Set a catalyst watch on the August facility extension and Alfamation remediation; failure to resolve either is a multiple-compression trigger even if revenue stays solid.
• If INTT reclaims its pre-earnings VWAP and management confirms Q3 gross margin near 44%, add to the long for a 10-20% tactical upside move; if not, fade rallies into strength.